Probucol
Modify Date: 2025-08-22 18:17:33
Probucol structure
|
Common Name | Probucol | ||
|---|---|---|---|---|
| CAS Number | 23288-49-5 | Molecular Weight | 516.842 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 546.7±50.0 °C at 760 mmHg | |
| Molecular Formula | C31H48O2S2 | Melting Point | 117 118ºC | |
| MSDS | Chinese USA | Flash Point | 264.9±28.8 °C | |
Use of ProbucolProbucol is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.Target: OthersProbucol is a drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. Probucol inhibited cholesterol efflux up to 80% in J774 macrophages expressing ABCA1. probucol is an effective inhibitor of ABCA1-mediated cholesterol efflux without influencing scavenger receptor class B type I-mediated efflux. The inhibition of ABCA1 translocation to the plasma membrane may in part explain the reported in vivo high-density lipoprotein-lowering action of probucol [1]. |
| Name | probucol |
|---|---|
| Synonym | More Synonyms |
| Description | Probucol is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.Target: OthersProbucol is a drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. Probucol inhibited cholesterol efflux up to 80% in J774 macrophages expressing ABCA1. probucol is an effective inhibitor of ABCA1-mediated cholesterol efflux without influencing scavenger receptor class B type I-mediated efflux. The inhibition of ABCA1 translocation to the plasma membrane may in part explain the reported in vivo high-density lipoprotein-lowering action of probucol [1]. |
|---|---|
| Related Catalog | |
| References |
[1]. Probucol |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 546.7±50.0 °C at 760 mmHg |
| Melting Point | 117 118ºC |
| Molecular Formula | C31H48O2S2 |
| Molecular Weight | 516.842 |
| Flash Point | 264.9±28.8 °C |
| Exact Mass | 516.309570 |
| PSA | 91.06000 |
| LogP | 10.27 |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.574 |
| InChIKey | FYPMFJGVHOHGLL-UHFFFAOYSA-N |
| SMILES | CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1 |
| Storage condition | Desiccate at +4°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Safety Phrases | S23-S24/25 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | AL3705000 |
| HS Code | 29093090 |
|
~82%
Probucol CAS#:23288-49-5 |
| Literature: Sumitomo Chemical Company, Limited Patent: EP1849768 A1, 2007 ; Location in patent: Page/Page column 5 ; |
| Precursor 2 | |
|---|---|
| DownStream 9 | |
CAS#:110-94-1
CAS#:719-22-2![2,6-ditert-butyl-4-[(3,5-ditert-butyl-4-hydroxyphenyl)disulfanyl]phenol structure](https://image.chemsrc.com/caspic/049/6386-58-9.png)
CAS#:6386-58-9![2,6-ditert-butyl-4-[(3,5-ditert-butyl-4-hydroxyphenyl)trisulfanyl]phenol structure](https://image.chemsrc.com/caspic/108/6386-61-4.png)
CAS#:6386-61-4
CAS#:2455-14-3
CAS#:216167-82-7
CAS#:216168-45-5
CAS#:216167-95-2
CAS#:110-15-6| HS Code | 2930909090 |
|---|---|
| Summary | 2930909090. other organo-sulphur compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Chem. Res. Toxicol. 23 , 171-83, (2010) Drug-induced liver injury is one of the main causes of drug attrition. The ability to predict the liver effects of drug candidates from their chemical structures is critical to help guide experimental... |
|
|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
J. Sci. Ind. Res. 65(10) , 808, (2006) Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI typ... |
|
|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Chem. Res. Toxicol. 23 , 1215-22, (2010) Drug-induced liver injury is a major issue of concern and has led to the withdrawal of a significant number of marketed drugs. An understanding of structure-activity relationships (SARs) of chemicals ... |
| 4,4'-(Isopropylidenedithio)bis[2,6-di-tert-butylphenol] |
| Biphenabid |
| Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)- |
| Lursell |
| EINECS 245-560-9 |
| Probucol |
| 2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol |
| Acetone Bis(3,5-di-tert-butyl-4-hydroxyphenyl)mercaptole |
| Bisbid |
| [14C]-Probucol |
| Panavir |
| Sinlestal |
| Lurselle |
| 4,4'-((1-methylethylidene)-bis(thio))-bis(2,6-bis(1,1-dimethylethyl)phenol) |
| 4,4'-[(1-methylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)phenol] |
| 4,4'-(propane-2,2-diyldisulfanediyl)bis(2,6-di-tert-butylphenol) |
| 4,4'-[(1-Methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)phenol] |
| Probucolum |
| MFCD00079281 |
| Lesterol |
| Lorelco |
| Bisphenabid |
| 4,4'-(isopropylidenedithio)-bis-(2,6-di-tert-butylphenol) |
| 4,4'-(2,2-Propanediyldisulfanediyl)bis[2,6-bis(2-methyl-2-propanyl)phenol] |